Top

Published in:

01-10-2011

Novel Concepts in the Genesis of Hypertension: Role of LOX-1

Authors: Ping Luo, Meiling Yan, Edward D. Frohlich, Jawahar L. Mehta, Changping Hu

Published in: Cardiovascular Drugs and Therapy | Issue 5/2011

Abstract

Hypertension is a common disease and a potent risk factor for cardiovascular disease. Tremendous strides have been made in understanding its genesis in the last 2 decades. Hypertension is often clustered with other cardiovascular risk factors, such as dyslipidemia and diabetes. The state of hypertension is often associated with increased vascular oxidative stress. Oxidative stress promotes proliferation and hypertrophy of vascular smooth muscle cell and collagen deposition, leading to thickening of the vascular media and narrowing of the vascular lumen. Oxidative stress also injures endothelium, impairs endothelium-dependent vascular relaxation and increases vascular contractile activity. Further, oxidative stress also oxidizes LDL-cholesterol. It has been shown that oxidized low-density lipoprotein (ox-LDL) activates renin-angiotensin system (RAS) and angiotensin II via its type 1 receptor activates ox-LDL receptor LOX-1. This mutually facilitative cross-talk between ox-LDL and RAS may be an important component in the development of hypertension. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a receptor for ox-LDL. This review summarizes the role of LOX-1 in the pathogenesis of hypertension.

Grossman E. Does increased oxidative stress cause hypertension? Diabetes Care. 2008;31:S185–9.PubMedCrossRef

Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93:621–35 (Frohlich ED, Editor).PubMedCrossRef

Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73–7.PubMedCrossRef

Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J. 1998;334:9–13.PubMed

Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K, et al. Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:955–60.PubMedCrossRef

Chen M, Kakutani M, Naruko T, Ueda M, Narumiya S, Masaki T, et al. Activation-dependent surface expression of LOX-1 in human platelets. Biochem Biophys Res Commun. 2001;282:153–8.PubMedCrossRef

Hu C, Dandapat A, Sun L, Khan JA, Liu Y, Hermonat PL, et al. Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem. 2008;283:10226–31.PubMedCrossRef

Hu CP, Dandapat A, Liu Y, Hermonat PL, Mehta JL. Blockade of hypoxia-reoxygenation-mediated collagen type I expression and MMP activity by overexpression of TGF-beta1 delivered by AAV in mouse cardiomyocytes. Am J Physiol Heart Circ Physiol. 2007;293:H1833–8.PubMedCrossRef

Hu CP, Mehta JL. Biology of LOX-1 in relation to atherogenesis. Future lipidol. 2008;3:689–96.CrossRef

10.

Nagase M, Hirose S, Sawamura T, Masaki T, Fujita T. Enhanced expression of endothelial oxidized low-density lipoprotein receptor (LOX-1) in hypertensive rats. Biochem Biophys Res Commun. 1997;237:496–8.PubMedCrossRef

11.

Hu C, Chen J, Dandapat A, Fujita Y, Inoue N, Kawase Y, et al. LOX-1 abrogation reduces myocardial ischemia-reperfusion injury in mice. J Mol Cell Cardiol. 2008;44:76–83.PubMedCrossRef

12.

Sankaralingam S, Xu H, Jiang Y, Sawamura T, Davidge ST. Evidence for increased methylglyoxal in the vasculature of women with preeclampsia: role in upregulation of LOX-1 and arginase. Hypertension. 2009;54:897–904.PubMedCrossRef

13.

Navarra T, Del Turco S, Berti S, Basta G. The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb. 2010;17:317–31.PubMedCrossRef

14.

Aoyama T, Fujiwara H, Masaki T, Sawamura T. Induction of lectin-like oxidized LDL receptor by oxidized LDL and lysophosphatidylcholine in cultured endothelial cells. J Mol Cell Cardiol. 1999;31:2101–14.PubMedCrossRef

15.

Chen J, Liu Y, Liu H, Hermonat PL, Mehta JL. Molecular dissection of angiotensin II-activated human LOX-1 promoter. Arterioscler Thromb Vasc Biol. 2006;26:1163–8.PubMedCrossRef

16.

Hofnagel O, Luechtenborg B, Stolle K, Lorkowski S, Eschert H, Plenz G, et al. Proinflammatory cytokines regulate LOX-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004;24:1789–95.PubMedCrossRef

17.

Murase T, Kume N, Korenaga R, Ando J, Sawamura T, Masaki T, et al. Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83:328–33.PubMed

18.

Gobal F, Deshmukh A, Shah S, Mehta JL. Triad of metabolic syndrome, chronic kidney disease, and coronary heart disease with a focus on microalbuminuria death by overeating. J Am Coll Cardiol. 2011;57:2303–8.PubMedCrossRef

19.

Ward NC, Croft KD. Hypertension and oxidative stress. Clin Exp Pharmacol Physiol. 2006;33:872–6.PubMedCrossRef

20.

Wang D, Strandgaard S, Iversen J, Wilcox CS. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol. 2009;296:R195–200.PubMedCrossRef

21.

Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002;346:1954–62.PubMedCrossRef

22.

Lip GY, Edmunds E, Nuttall SL, Landray MJ, Blann AD, Beevers DG. Oxidative stress in malignant and non-malignant phase hypertension. J Hum Hypertens. 2002;16:333–6.PubMedCrossRef

23.

Lee VM, Quinn PA, Jennings SC, Ng LL. Neutrophil activation and production of reactive oxygen species in pre-eclampsia. J Hypertens. 2003;21:395–402.PubMedCrossRef

24.

Kimura H, Kon N, Furukawa S, Mukaida M, Yamakura F, Matsumoto K, et al. Effect of endurance exercise training on oxidative stress in spontaneously hypertensive rats (SHR) after emergence of hypertension. Clin Exp Hypertens. 2010;32:407–15.PubMedCrossRef

25.

Hu C, Dandapat A, Sun L, Marwali MR, Inoue N, Sugawara F, et al. Modulation of angiotensin II-mediated hypertension and cardiac remodeling by lectin-like oxidized low-density lipoprotein receptor-1 deletion. Hypertension. 2008;52:556–62.PubMedCrossRef

26.

Naito Y, Hirotani S, Sawada H, Akahori H, Tsujino T, Masuyama T. Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension. 2011;57:497–504.PubMedCrossRef

27.

Vaziri ND. Mechanisms of lead-induced hypertension and cardiovascular disease. Am J Physiol Heart Circ Physiol. 2008;295:H454–65.PubMedCrossRef

28.

Bełtowski J, Borkowska E, Wójcicka G, Marciniak A. Regulation of renal ouabain-resistant Na⁺-ATPase by leptin, nitric oxide, reactive oxygen species, and cyclic nucleotides: implications for obesity-associated hypertension. Clin Exp Hypertens. 2007;29:189–207.PubMedCrossRef

29.

Dunbar DR, Khaled H, Evans LC, Al-Dujaili EA, Mullins LJ, Mullins JJ, et al. Transcriptional and physiological responses to chronic ACTH treatment by the mouse kidney. Physiol Genomics. 2010;40:158–66.PubMedCrossRef

30.

Yogi A, Callera GE, O’Connor SE, He Y, Correa JW, Tostes RC, et al. Dysregulation of renal transient receptor potential melastatin 6/7 but not paracellin-1 in aldosterone-induced hypertension and kidney damage in a model of hereditary hypomagnesemia. J Hypertens. 2011;29:1400–10.PubMedCrossRef

31.

Ilhan S, Oktar S, Sahna E, Aksulu HE. Salt and nitric oxide inhibition induced hypertension: the role of prostacycline and 8-isoprostane. Clin Exp Hypertens. 2011;33:84–8.PubMedCrossRef

32.

Reis F, Rocha-Pereira P, Teixeira de Lemos E, Parada B, Baptista S, Figueiredo A, et al. Oxidative stress in cyclosporine-induced hypertension: evidence of beneficial effects or tolerance development with nitrate therapy. Transplant Proc. 2007;39:2494–500.PubMedCrossRef

33.

Nakano A, Inoue N, Sato Y, Nishimichi N, Takikawa K, Fujita Y, et al. LOX-1 mediates vascular lipid retention under hypertensive state. J Hypertens. 2010;28:1273–80.PubMed

34.

Saeed A, Dibona GF, Marcussen N, Guron G. High-NaCl intake impairs dynamic autoregulation of renal blood flow in ANG II-infused rats. Am J Physiol Regul Integr Comp Physiol. 2010;299:R1142–9.PubMedCrossRef

35.

Liu R, Ren Y, Garvin JL, Carretero OA. Superoxide enhances tubuloglomerular feedback by constricting the afferent arteriole. Kidney Int. 2004;66:268–74.PubMedCrossRef

36.

Wang T, Takabatake T. Effects of vasopeptidase inhibition on renal function and tubuloglomerular feedback in spontaneously hypertensive rats. Hypertens Res. 2005;28:611–8.PubMedCrossRef

37.

Hirooka Y. Oxidative stress in the cardiovascular center has a pivotal role in the sympathetic activation in hypertension. Hypertens Res. 2011;34:407–12.PubMedCrossRef

38.

Cheng WH, Lu PJ, Ho WY, Tung CS, Cheng PW, Hsiao M, et al. Angiotensin II inhibits neuronal nitric oxide synthase activation through the ERK1/2-RSK signaling pathway to modulate central control of blood pressure. Circ Res. 2010;106:788–95.PubMedCrossRef

39.

Ferrario C. Angiotensin-converting enzyme 2 and angiotensin (1–7): an evolving story in cardiovascular regulation. Hypertension. 2006;47:515–21.PubMedCrossRef

40.

Brody MJ. Central nervous system and mechanisms of hypertension. Clin Physiol Biochem. 1988;6:230–9.PubMed

41.

Peterson JR, Sharma RV, Davisson RL. Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep. 2006;8:232–41.PubMedCrossRef

42.

Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, et al. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res. 2002;91:1038–45.PubMedCrossRef

43.

Zimmerman MC, Lazartigues E, Sharma RV, Davisson RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res. 2004;95:210–6.PubMedCrossRef

44.

Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol. 2003;23:776–82.PubMedCrossRef

45.

Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol. 2006;2:582–93.PubMedCrossRef

46.

Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension. 2008;52:256–63.PubMedCrossRef

47.

Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449–60.PubMedCrossRef

48.

Nguyen Dinh Cat A, Touyz RM. Cell signaling of angiotensin II on vascular tone: novel mechanisms. Curr Hypertens Rep. 2011;13:122–8.PubMedCrossRef

49.

Re RN. The cellular biology of angiotensin; paracrine, autocrine and intracrine actions in cardiovascular tissues. J Mol Cell Cardiol. 1989;2:63–9.CrossRef

50.

Re RN. The nature of intracrine peptide mormone actions. Hypertension. 1999;34:534–8.PubMed

51.

Re RN, Cook JL. Chapter 9 Intracrine function from angiotensin to stem cells. In: Frohlich ED, Re RN, editors. The local cardiac renin-angiotensin aldosterone system. New York: Springer-Science Business Media, LLC; 2009. p. 91–100.CrossRef

52.

Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292–316.PubMedCrossRef

53.

Miura S, Saku K, Karnik SS. Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res. 2003;26:937–43.PubMedCrossRef

54.

Catar RA, Muller G, Heidler J, Schmitz G, Bornstein SR, Morawietz H. Low-density lipoproteins induce the renin-angiotensin system and their receptors in human endothelial cells. Horm Metab Res. 2007;39:801–5.PubMedCrossRef

55.

Chen J, Mehta JL. Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease. Curr Hypertens Rep. 2006;8:139–43.PubMedCrossRef

56.

Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis. 2006;184:295–301.PubMedCrossRef

57.

Marsche G, Levak-Frank S, Quehenberger O, Heller R, Sattler W, Malle E. Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells. FASEB J. 2001;15:1095–7.PubMed

58.

Oka K, Sawamura T, Kikuta K, Itokawa S, Kume N, Kita T, et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci USA. 1998;95:9535–40.PubMedCrossRef

59.

Honjo M, Nakamura K, Yamashiro K, Kiryu J, Tanihara H, McEvoy LM, et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci USA. 2003;100:1274–9.PubMedCrossRef

60.

Shimaoka T, Kume N, Minami M, Hayashida K, Sawamura T, Kita T, et al. LOX-1 supports adhesion of Gram-positive and Gram-negative bacteria. J Immunol. 2001;166:5108–14.PubMed

61.

Cominacini L, Fratta Pasini A, Garbin U, Pastorino A, Rigoni A, Nava C, et al. The platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells. J Am Coll Cardiol. 2003;41:499–507.PubMedCrossRef

62.

Murphy JE, Tacon D, Tedbury PR, Hadden JM, Knowling S, Sawamura T, et al. LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells. Biochem J. 2006;393:107–15.PubMedCrossRef

63.

Chen X, Zhang T, Du G. Advanced glycation end products serve as ligands for lectin-like oxidized low-density lipoprotein receptor-1(LOX-1): biochemical and binding characterizations assay. Cell Biochem Funct. 2008;26:760–70.PubMedCrossRef

64.

Li D, Saldeen T, Romeo F, Mehta JL. Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB. Circulation. 2000;102:1970–6.PubMed

65.

Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, et al. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem. 2009;55:285–94.PubMedCrossRef

66.

Taye A, Saad AH, Kumar AH, Morawietz H. Effect of apocynin on NADPH oxidase-mediated oxidative stress-LOX-1-eNOS pathway in human endothelial cells exposed to high glucose. Eur J Pharmacol. 2010;627:42–8.PubMedCrossRef

67.

Nagase M, Kaname S, Nagase T, Wang G, Ando K, Sawamura T, et al. Expression of LOX-1, an oxidized low-density lipoprotein receptor, in experimental hypertensive glomerulosclerosis. J Am Soc Nephrol. 2000;11:1826–36.PubMed

68.

Chiba Y, Ando K, Fujita T. The protective effects of taurine against renal damage by salt loading in Dahl salt-sensitive rats. J Hypertens. 2002;20:2269–74.PubMedCrossRef

69.

Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation. 1999;100:899–902.PubMed

70.

Kang BY, Hu C, Ryu S, Khan JA, Biancolella M, Prayaga S, et al. Genomics of cardiac remodeling in angiotensin II-treated wild-type and LOX-1-deficient mice. Physiol Genomics. 2010;42:42–54.PubMedCrossRef

71.

Kang BY, Khan JA, Ryu S, Shekhar R, Seung KB, Mehta JL. Curcumin reduces angiotensin II-mediated cardiomyocyte growth via LOX-1 inhibition. J Cardiovasc Pharmacol. 2010;55:417–24.PubMedCrossRef

72.

Kang BY, Mehta JL. Rosuvastatin attenuates Ang II–mediated cardiomyocyte hypertrophy via inhibition of LOX-1. J Cardiovasc Pharmacol Ther. 2009;14:283–91.PubMedCrossRef

73.

Kobayashi N, Hara K, Tojo A, Onozato ML, Honda T, Yoshida K, et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. Hypertension. 2005;45:538–44.PubMedCrossRef

74.

Zhou MS, Schuman IH, Jaimes EA, Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol. 2008;295:F53–9.PubMedCrossRef

75.

Hu C, Kang BY, Megyesi J, Kaushal GP, Safirstein RL, Mehta JL. Deletion of LOX-1 attenuates renal injury following angiotensin II infusion. Kidney Int. 2009;76:521–7.PubMedCrossRef

76.

Kang BY, Hu C, Prayaga S, Khaidakov M, Sawamura T, Seung KB, et al. LOX-1 dependent overexpression of immunoglobulins in cardiomyocytes in response to angiotensin II. Biochem Biophys Res Commun. 2009;379:395–9.PubMedCrossRef

77.

Kishimoto C, Takamatsu N, Kawamata H, Shinohara H, Ochiai H. Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change. J Am Coll Cardiol. 2000;36:1979–84.PubMedCrossRef

Title: Novel Concepts in the Genesis of Hypertension: Role of LOX-1
Authors: Ping Luo
Meiling Yan
Edward D. Frohlich
Jawahar L. Mehta
Changping Hu
Publication date: 01-10-2011
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue 5/2011
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-011-6337-1

2024 ASCO Annual Meeting

Springer Medicine

Novel Concepts in the Genesis of Hypertension: Role of LOX-1

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Oxidized Low Density Lipoproteins-Do We Know Enough About Them?

LOX-1/LOXIN: The Yin/Yang of Atheroscleorosis

LOX-1 Transcription

LOX-1: A Critical Player in the Genesis and Progression of Myocardial Ischemia

LOX-1: A New Target for Therapy for Cardiovascular Diseases

LOX-1 and Obesity